2024 Archives - Page 4 of 4 - MaaT Pharma

Press Releases

March 19, 2024: MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’…

MaaT PharmaMarch 19, 2024

Press Releases

March 12, 2024: MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference

MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be…

MaaT PharmaMarch 12, 2024

Press Releases

March 7, 2024: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…

MaaT PharmaMarch 7, 2024

Press Releases

March 7, 2024: MaaT Pharma Releases its 2024 Financial Calendar

MaaT Pharma Releases its 2024 Financial Calendar Lyon, France, March 7, 2024 –6:00pm CET –…

MaaT PharmaMarch 7, 2024

Press Releases

March 5, 2024: MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma

MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial…

MaaT PharmaMarch 5, 2024

Previous 1 2 3 4

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club